Not holding back

Pharmaceutical Technology lets us tell ’em how we really feel about Novo asking the FDA to put semaglutide on the Demonstrably Difficult to Compound list.

Alliance for Pharmacy Compounding’s CEO Scott Brunner did not hold back in a statement following Novo Nordisk’s request, citing “desperation” and “ridiculous claims” made by the drugmaker.